Hangzhou, China
BIOEAST is a leading high-tech enterprise in the biotechnology and healthcare industries, focusing on pioneering research and development of key raw materials for In-Vitro Diagnostic, Life Science, and Biomedical reagent solutions. Founded in 2018 in China, the company has quickly established itself as a trusted provider of innovative solutions in the industry.
The company specializes in developing advanced technologies and cutting-edge solutions to meet the evolving needs of the diagnostic, life science, and biomedical sectors. Its product portfolio includes a wide range of offerings, such as microspheres, antigens, antibodies, enzymes, active proteins, chromatographic products, and integrated solutions for various diagnostic platforms.
BIOEAST's last investment was a CNY150.00M Series A investment on 09 May 2022, with participation from prominent investors including Cowin Venture, LYFE Capital, Huachuang Zhiye Capital, and YuanSheng Ventures. The company also operates two wholly-owned companies, AICHEK and BiogenMicro, to serve manufacturers with customized solutions in the industry.
With its leading R&D and manufacturing facilities, ISO13485 certified quality system, and round-the-clock technical support, BIOEAST has successfully served hundreds of manufacturers and is committed to driving innovation in the industry by collaborating with its partners to create a glorious future together.
